Presentation is loading. Please wait.

Presentation is loading. Please wait.

BSRBR-RA UK CRN ID: 7302 August 2013 update. Recruitment Certolizumab Must have diagnosis of RA Must be registered within 6 months of first dose of certolizumab.

Similar presentations


Presentation on theme: "BSRBR-RA UK CRN ID: 7302 August 2013 update. Recruitment Certolizumab Must have diagnosis of RA Must be registered within 6 months of first dose of certolizumab."— Presentation transcript:

1 BSRBR-RA UK CRN ID: 7302 August 2013 update

2 Recruitment Certolizumab Must have diagnosis of RA Must be registered within 6 months of first dose of certolizumab Can be re-registered if already on the study Tocilizumab Must have diagnosis of RA Must be registered within 6 months of first dose of tocilizumab Can be re-registered if already on the study Anti-TNF Comparison Cohort Must have diagnosis of RA Must be registered within 6 months of first dose of etanercept, adalimumab or infliximab Numbers recruited up to 25/07/ As of 25/07/ As of 25/07// As of 25/07//2013

3 Recruitment July 2011July 2013 Certolizumab recruitment by month Tocilizumab recruitment by month Anti-TNF cohort recruitment by month Dec2011July July 2011 July

4 Recruitment 01/01/2013 – 19/07/2013 BSR Region Number recruited since 1st January 2013 North West90 East Midlands89 Yorkshire and the Humber85 West Midlands64 South West61 Mersey49 London (South)22 South Central21 North East18 South East18 East of England17 London Central and North East17 Scotland14 London (North West)13 Wales8 Northern Ireland3

5 BSR Region Awards January - July 2013 North West East Midlands Yorkshire and the Humber

6 Help is available with the BSRBR-RA If you do not have enough staff support currently, then in England the National Institute for Health Research Comprehensive Clinical Research Network (CCRN) may be able to provide assistance What is the CCRN? The CCRN is made up of 25 Comprehensive Local Research Networks (CLRNs) which cover the whole of England. Each local Network facilitates research within their region, with the aim of widening participation in research. A study is eligible for CLRN assistance if it has been adopted on to the Network portfolio of studies; the BSRBR-RA was adopted on to this portfolio in 2008 (ID: 7302). How can my CLRN help me? The CLRN may be able to help by assisting in R&D set up or by providing funding for the people/facilities you require in order to carry out research in which you are involved in. For example, you may be allocated research nurse time or a data clerk to assist with the recruitment and follow up of participants on the BSRBR-RA. How can I apply for CLRN help? You should contact the team within your regional network (details found via the link below) to discuss your requirements. You will then have to complete an application form, with which we can help. The BSRBR-RA Study reference number within the Network is 7302 – please remember to quote this when asking for help with the study. If you need any help with completing the paperwork, please contact

7 Is there help outside of England? Regional Support Northern Ireland The Northern Ireland Clinical Research Network (NICRN) may be able to provide assistance in Northern Ireland in the same way as the NIHR CCRN in England, please contact the team to discuss requirements: Wales The National Institute for Social Care and Health Research Clinical Research Centre (NISCHR CRC) may be able to provide assistance in Wales in the same way as the NIHR CCRN in England, please contact the team to discuss requirements: Scotland NHS Scotland may be able to provide assistance in Scotland in the same way as the NIHR CCRN in England, please contact the team to discuss if support is possible for you : _ClinicalResearchNetworks.html

8 Recent BSRBR-RA publications – Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population. Mercer, L., Davies, R., Galloway, J., Low, A., Lunt, M., Dixon, W., Watson, K., Symmons, D., Hyrich, K. & BSRBR_Control_Centre Consortium, B (2013). Rheumatology (Oxford), 52(1), – Anti-TNF therapy in women with rheumatoid arthritis with a history of carcinoma in situ of the cervix. Mercer, L., Low, A., Galloway, J., Watson, K., Lunt, M., Symmons, D., Hyrich, K. & BSRBR_Control_Centre_Consortium, B (2013). Ann Rheum Dis, 72(1), – The risk of gastrointestinal perforations in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the BSRBR-RA. Závada, J., Lunt, M., Davies, R., Low, A., Mercer, L., Galloway, J., Watson, K., Symmons, D., Hyrich, K. &, B (2013). Ann Rheum Dis, [Epub ahead of print]

9 Accessing BSRBR-RA data

10 Recent/ongoing research projects via the BSRBR-RA data access scheme  Non-inflammatory pain mechanisms as confounders in the clinical assessment of synovitis in RA  Study of fatigue in inflammatory arthritis  Effectiveness of TNF response define by season of initiation of therapy, with particular focus on vitamin D  To explore the influence of gender and gender-related variables on severity of prognosis for RA  Obesity and clinical response to anti-TNF medication

11 2) ACR conference 2013 – San Diego 1. Non-differential Reporting of Myocardial Infarction to a National Observational Drug Safety Study Using Linked Data: Linkage of the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis and the Myocardial Ischaemia National Audit Project. 2. Comparison of the Occurrence and Severity of Myocardial Infarction in Subjects with Rheumatoid Arthritis Receiving Tumour Necrosis Factor Inhibitors or Standard Non-biologic Disease Modifying Anti-rheumatic Drugs: Results from a Linkage between the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis and the Myocardial Ischaemia National Audit Project. 3. The risk of serious infections in patients receiving rituximab for rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis. BSRBR-RA abstracts submitted:

12 What to look out for soon 1) Web portal development The Robertson Centre at the University of Glasgow are developing a new web portal for online data capture. The portal will include the facility to register new patients as well as enter follow-up data for patients already on the study

13 Acknowledgements UK Consultant Rheumatologists and Specialist Nurses Comprehensive Local Research Networks BSRBR Control Centre Consortium British Society for Rheumatology Arthritis Research UK Epidemiology Unit, Manchester


Download ppt "BSRBR-RA UK CRN ID: 7302 August 2013 update. Recruitment Certolizumab Must have diagnosis of RA Must be registered within 6 months of first dose of certolizumab."

Similar presentations


Ads by Google